Extended-Release Oxybutynin for the Treatment of Neurogenic Detrusor Overactivity

NCT01796548 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

17

Enrollment

INDUSTRY

Sponsor class

Stopped Slow rate of participant's enrollment

Conditions

Detrusor Function, Overactive

Interventions

DRUG: Oxybutinin Extended-Release

Sponsor

Janssen-Cilag Ltd.,Thailand